Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;59(2):282-284.
doi: 10.1038/s41409-023-02165-3. Epub 2023 Dec 9.

Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease

Iskra Pusic  1 , Catherine Lee  2 , Muthu Veeraputhiran  3 , Chelsea Minor  4 , John F DiPersio  4
Affiliations

Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease

Iskra Pusic et al. Bone Marrow Transplant. 2024 Feb.
No abstract available

PubMed Disclaimer

References

    1. Arora M, Cutler CS, Jagasia MH, Pidala J, Chai X, Martin PJ, et al. Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2016;22:449–55. https://doi.org/10.1016/j.bbmt.2015.10.018 . - DOI
    1. Lee SJ, Nguyen TD, Onstad L, Bar M, Krakow EF, Salit RB, et al. Success of immunosuppressive treatments in patients with chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2018;24:555–62. https://doi.org/10.1016/j.bbmt.2017.10.042 . - DOI
    1. Wolff D, Fatobene G, Rocha V, Kroger N, Flowers ME. Steroid-refractory chronic graft-versus-host disease: treatment options and patient management. Bone Marrow Transpl. 2021;56:2079–87. https://doi.org/10.1038/s41409-021-01389-5 . - DOI
    1. Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N. Engl J Med. 2021;385:228–38. https://doi.org/10.1056/NEJMoa2033122 . - DOI - PubMed
    1. Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021;138:2278–89. https://doi.org/10.1182/blood.2021012021 . - DOI - PubMed - PMC

LinkOut - more resources